Risk Analysis for Merck and Company: Pro...
Bodily, Samuel E.,...
Risk Analysis for Merck and Company: Product KL-798
Bodily, Samuel E.; Faulk, John
QA-0600 | Published September 25, 2003 | 8 pages Case
Collection: Darden School of Business
Product Details
This case builds on the case "Merck & Company: Product KL-798" (UVA-QA-0582) by providing market uncertainties for the drug (drug quality, the presence of a competitor, market growth, and the time to the drug's release). Student and faculty spreadsheets are provided for the calculation of net present values for the scenarios. There is an additional challenge of how to treat the several downstream decisions (using OptQuest, for example) and how to value the license opportunity. A teaching note is also available to registered faculty members.
0
Products to Upsell
Chains
Larson, Andrea
Terminal Values, Multiples, and Competit...
Harris, Robert S.
Leading with Vulnerability
Belmi, Peter; Thom...
Accounting for Owners’ Equity
Lynch, Luann J.; B...
Share Repurchases
Loutskina, Elena
Finance People
Schill, Michael J.
Ought to "Can": Questions for an Entrepr...
Sarasvathy, Saras ...
Jonathan Virginia, Inc.
Hess, Edward D.